文献速递胸部肿瘤

FLAURA试验患者报告结局:奥希替尼对比厄洛替尼/吉非替尼

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
PubMed 文献 · Eur J Cancer · 2019-12-12

FLAURA试验中556例EGFR突变晚期非小细胞肺癌患者随机接受奥希替尼或厄洛替尼/吉非替尼治疗,完成EORTC QLQ-LC13和QLQ-C30问卷。两臂关键症状均较基线改善,但均未达到临床意义的组间差异;事后分析显示奥希替尼在情绪功能、社会功能和认知功能方面更优。

要点

  • 两治疗臂关键症状均较基线改善,但无统计学显著且临床意义的组间差异。
  • 奥希替尼组胸痛改善虽具统计学显著性(p=0.021),但未达临床意义阈值。
  • 事后分析中奥希替尼在情绪功能、社会功能及认知功能方面优于对照臂。

核心结论

  • FLAURA试验中奥希替尼与厄洛替尼/吉非替尼两臂的关键症状均较基线改善,但未观察到任一治疗臂在关键症状上同时具有统计学显著性和临床意义的改善。

研究设计与样本

  • FLAURA试验纳入556例EGFR突变晚期非小细胞肺癌患者,随机接受奥希替尼或厄洛替尼/吉非替尼治疗。
  • 患者每周完成EORTC QLQ-LC13问卷共6周,之后每3周一次;每6周完成QLQ-C30问卷。
  • 预设关键症状为咳嗽、呼吸困难、胸痛、食欲丧失和疲乏,采用混合效应模型评估从基线至随机治疗终止的评分变化,≥10分变化视为临床相关。

主要发现

  • 问卷完成率在多数时间点>70%,奥希替尼与厄洛替尼/吉非替尼两臂基线平均评分相似。
  • 两臂评分均改善,但均未在5%显著性水平达到临床相关性。
  • 胸痛方面奥希替尼组改善具统计学显著差异(-6.84 vs -3.88;p=0.021),但未达临床相关性。
  • 两治疗臂在改善几率和至恶化时间方面相似。
  • 事后分析中,奥希替尼组情绪功能改善更优(8.79 vs 4.91;p=0.004),社会功能改善更优(7.66 vs 1.74;p<0.001)。

关键数值与推荐

  • 评分变化≥10分被视为临床相关。
  • 胸痛评分变化:奥希替尼组-6.84,厄洛替尼/吉非替尼组-3.88,p=0.021。
  • 情绪功能评分变化:奥希替尼组8.79,厄洛替尼/吉非替尼组4.91,p=0.004。
  • 社会功能评分变化:奥希替尼组7.66,厄洛替尼/吉非替尼组1.74,p<0.001。
  • 认知功能评分变化:奥希替尼组0.03,厄洛替尼/吉非替尼组-3.91,p=0.005。

临床怎么用

  • 对于EGFR突变晚期非小细胞肺癌患者,奥希替尼一线治疗在关键症状改善方面与厄洛替尼/吉非替尼相似。
  • 奥希替尼可能有助于维持认知功能,并在情绪和社会功能方面带来额外获益。

局限性

  • 关键症状的组间差异均未同时达到统计学显著性和临床相关性。
  • 情绪功能、社会功能和认知功能的分析为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the FLAURA trial, osimertinib demonstrated superior progression-free survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients with EGFR-mutated advanced non-small-cell lung cancer. Patient-reported outcomes from FLAURA are discussed here. METHODS: Patients (N = 556) completed the EORTC QLQ-LC13 weekly for 6 weeks, then every 3 weeks, and the QLQ-C30 every 6 weeks. Prespecified key symptoms were cough, dyspnea, chest pain, appetite loss, and fatigue. Score changes from baseline to randomized treatment discontinuation were assessed using a mixed-effects model. A ≥10-point change was considered clinically relevant. Odds of improvement and time to deterioration were investigated. QLQ-C30 functioning scores were assessed post hoc. RESULTS: Questionnaire completion rates were >70% at most time points. Baseline mean scores were similar in the osimertinib and erlotinib/gefitinib arms. Scores improved in both arms, but none reached clinical relevance at 5% significance level. A statistically significant difference favoring osimertinib for chest pain was not clinically relevant (-6.84 vs -3.88; p = 0.021). Odds of improvement and time to deterioration were similar between treatments. In post hoc analyses, improvements favored osimertinib for emotional functioning (8.79 vs 4.91; p = 0.004) and social functioning (7.66 vs 1.74; p < 0.001). Cognitive functioning remained stable with osimertinib but deteriorated with erlotinib/gefitinib (0.03 vs -3.91; p = 0.005). CONCLUSIONS: Key symptoms improved from baseline in both treatment arms in FLAURA. Key symptom improvements that were both statistically significant and clinically relevant were not observed in favor of either treatment arm. CLINICAL TRIAL REGISTRATION: NCT02296125.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Leighl NB, Karaseva N, Nakagawa K, et al. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer. 2019. PMID: 31838405. doi:10.1016/j.ejca.2019.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。